Thus, the initial goal of the GIP technology platform was to eventually make GIP-34 and its growth inhibitory subcomponents available as peptide drugs for adults afflicted with benign hyperplasia and cancer growth as seen in hepatic, reproductive, and gastrointestinal tumors. This evidence concerns the gene GIP and cancer.